Pitcairn Co. decreased its position in shares of Allergan plc (NYSE:AGN) by 3.4% during the second quarter, Holdings Channel reports. The institutional investor owned 4,065 shares of the company’s stock after selling 141 shares during the period. Pitcairn Co.’s holdings in Allergan plc were worth $939,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the stock. Capstone Asset Management Co. boosted its stake in shares of Allergan plc by 0.6% in the first quarter. Capstone Asset Management Co. now owns 14,787 shares of the company’s stock valued at $3,963,000 after buying an additional 86 shares during the last quarter. Davis R M Inc. boosted its stake in shares of Allergan plc by 11.5% in the first quarter. Davis R M Inc. now owns 2,154 shares of the company’s stock valued at $577,000 after buying an additional 223 shares during the last quarter. Gillespie Robinson & Grimm Inc. boosted its stake in shares of Allergan plc by 2.1% in the first quarter. Gillespie Robinson & Grimm Inc. now owns 78,043 shares of the company’s stock valued at $16,948,000 after buying an additional 1,632 shares during the last quarter. Regent Investment Management LLC boosted its stake in shares of Allergan plc by 1.0% in the first quarter. Regent Investment Management LLC now owns 4,619 shares of the company’s stock valued at $1,238,000 after buying an additional 44 shares during the last quarter. Finally, OLD National Bancorp IN boosted its stake in shares of Allergan plc by 0.6% in the first quarter. OLD National Bancorp IN now owns 32,693 shares of the company’s stock valued at $8,763,000 after buying an additional 188 shares during the last quarter. Institutional investors own 85.19% of the company’s stock.

Allergan plc (NYSE:AGN) traded up 2.11% during trading on Thursday, reaching $243.43. The company’s stock had a trading volume of 3,055,749 shares. The firm has a market capitalization of $96.39 billion, a P/E ratio of 23.18 and a beta of 0.73. The stock has a 50-day moving average of $244.93 and a 200 day moving average of $243.01. Allergan plc has a one year low of $195.50 and a one year high of $322.68.

Allergan plc (NYSE:AGN) last posted its quarterly earnings results on Monday, August 8th. The company reported $3.35 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.34 by $0.01. The business had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $4.10 billion. Allergan plc had a return on equity of 7.67% and a net margin of 28.06%. The company’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.41 EPS. On average, equities research analysts predict that Allergan plc will post $14.01 EPS for the current fiscal year.

AGN has been the topic of several recent research reports. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Allergan plc in a research note on Wednesday, July 6th. Leerink Swann upped their price target on Allergan plc from $272.00 to $294.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 27th. JPMorgan Chase & Co. set a $325.00 price target on Allergan plc and gave the stock a “buy” rating in a research note on Friday, August 5th. Zacks Investment Research cut Allergan plc from a “buy” rating to a “hold” rating in a research note on Tuesday, July 26th. Finally, Vetr raised Allergan plc from a “buy” rating to a “strong-buy” rating and set a $285.60 price target on the stock in a research note on Monday, August 1st. Seven investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $308.54.

Allergan plc Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

5 Day Chart for NYSE:AGN

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Receive News & Ratings for Allergan plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan plc and related companies with MarketBeat.com's FREE daily email newsletter.